Ancora Advisors LLC Makes New Investment in Emergent Biosolutions Inc. $EBS

Key Points

• Ancora Advisors acquired 1,067,867 Emergent BioSolutions shares worth approximately $8.95 million, giving it a 2.08% stake. Institutional investors collectively own 78.40% of EBS.
• Emergent reported quarterly revenue of $234.3 million and adjusted earnings of $0.60 per share, beating analyst expectations, although the company remains unprofitable on a net-margin basis.
• EBS shares opened at $5.64, well below their 52-week high of $14.06. Analyst sentiment is mixed, with an average “Hold” rating and a consensus price target of $10.00.

Ancora Advisors LLC acquired a new stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 1,067,867 shares of the biopharmaceutical company's stock, valued at approximately $8,949,000. Ancora Advisors LLC owned about 2.08% of Emergent Biosolutions as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in EBS. CWM LLC increased its position in Emergent Biosolutions by 5.5% in the fourth quarter. CWM LLC now owns 18,009 shares of the biopharmaceutical company's stock worth $223,000 after purchasing an additional 942 shares during the period. Franklin Resources Inc. raised its holdings in Emergent Biosolutions by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 78,945 shares of the biopharmaceutical company's stock worth $976,000 after purchasing an additional 1,764 shares during the last quarter. SG Americas Securities LLC lifted its position in Emergent Biosolutions by 4.6% during the 1st quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company's stock valued at $352,000 after purchasing an additional 1,865 shares during the period. Deutsche Bank AG lifted its position in Emergent Biosolutions by 1.1% during the 4th quarter. Deutsche Bank AG now owns 181,744 shares of the biopharmaceutical company's stock valued at $2,246,000 after purchasing an additional 1,941 shares during the period. Finally, Values First Advisors Inc. boosted its stake in shares of Emergent Biosolutions by 0.9% in the 1st quarter. Values First Advisors Inc. now owns 307,880 shares of the biopharmaceutical company's stock valued at $2,555,000 after purchasing an additional 2,834 shares during the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the company's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the sale, the senior vice president owned 159,098 shares in the company, valued at $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by company insiders.

Emergent Biosolutions Stock Performance

Shares of EBS stock opened at $5.64 on Wednesday. The stock has a market cap of $289.27 million, a P/E ratio of -1.59 and a beta of 2.35. The company has a fifty day moving average price of $7.00 and a two-hundred day moving average price of $8.17. Emergent Biosolutions Inc. has a one year low of $4.36 and a one year high of $14.06. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The company had revenue of $234.30 million for the quarter, compared to analysts' expectations of $177.50 million. As a group, equities analysts predict that Emergent Biosolutions Inc. will post -4.63 EPS for the current year.

Wall Street Analyst Weigh In

EBS has been the subject of several analyst reports. UBS Group restated a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings upgraded Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a research note on Friday. Benchmark reaffirmed a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. HC Wainwright lowered their price target on shares of Emergent Biosolutions from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Finally, Zacks Research raised shares of Emergent Biosolutions to a "hold" rating in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Emergent Biosolutions has an average rating of "Hold" and an average target price of $10.00.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source